Orig3n FDA Grants EUAs to Coronavirus Tests From Orig3n, SDI, UNC The FDA has also granted emergency use authorization for PCR-based tests for SARS-CoV-2 developed by Orig3n, Specialty Diagnostic Laboratories (SDI), and the University of North Carolina (UNC) Medical Center. Orig3n's Purchase of Interleukin's CLIA Lab May Appease CMS, But Some Question Plans for Test Assets Premium A number of experts have questioned the clinical validity underlying Interleukin's tests and hope Orig3n will not revive them. Orig3n Acquires Interleukin Genetics CLIA Lab, Remaining Assets Interleukin said in July that it would liquidate its assets after laying off 63 percent of its workforce and suspending sales of its controversial genetic test. Dental Association Advances Resolution on Genetic Test Validity The American Dental Association wants insurers and test manufacturers to show genetic testing is scientifically valid before they're used to determine coverage eligibility. Interleukin Genetics to Liquidate Assets The announcement comes three weeks after Interleukin said it was laying off 63 percent of its workforce and suspending sales of a controversial genetic test. Jul 11, 2017 Controversial Gum Disease Risk Test Highlights Precision Medicine Marketing, Regulatory Issues Jul 4, 2017 Interleukin Shutting Down Genetic Testing Program, Lays Off Staff May 12, 2017 In Brief This Week: Alere, Fulgent Diagnostics, Trovagene, Great Basin, and More Aug 1, 2016 Interleukin Genetics to Sell $5.6M in Stock, Warrants May 16, 2016 Interleukin Posts Increased Q1 Revenues Mar 17, 2016 Interleukin Genetics Q4 Revenues Up 14 Percent Nov 13, 2015 Interleukin Genetics Q3 Revenues Down 59 Percent on Fewer Processed Test Kits Nov 10, 2015 FDA Sends Interleukin Genetics, DNA-CardioCheck Untitled Letters Aug 14, 2015 Interleukin Genetics' Q2 Revenues Decline 29 Percent Jul 15, 2015 Interleukin, NYU to Commercialize IL-1 Genetic Test for Osteoarthritis Progression May 15, 2015 Interleukin Genetics Q1 Revenues Drop 17 Percent Mar 24, 2015 Divergent Findings on Interleukin Gum Disease Risk Test Raise Questions about Clinical Use Premium Mar 20, 2015 Interleukin Posts Q4 Revenue Drop as It Continues Commercial Push for PerioPredict Mar 9, 2015 Interleukin Genetics, Isis Pharma Expand Drug Testing Collaboration Jan 7, 2015 Interleukin Genetics to Provide Testing Services to Isis for Clinical Study Dec 24, 2014 Interleukin Genetics Secures $10M in Financing Apr 22, 2014 New York Conditionally Approves Interleukin to Provide Genetic Test for Periodontal Disease Mar 21, 2014 Interleukin Genetics Nearly Doubles Revenues in Q4 Jun 12, 2013 Interleukin Publishes Large Study Involving PST Test to Stratify Patients at Risk of Gum Disease Premium May 20, 2013 Interleukin Genetics Raises $12M in Private Placement Load More Breaking News Alzheimer's Disease Phosphoproteomics Study Uncovers Signaling Abnormalities Genetic Analysis of H. Pylori Indicates Americas Colonized in One Main Migration Event BillionToOne Raises $55M in Series B Financing GeninCode to Launch Cardiovascular Disease Risk Tests in US With Eversana Top Five Articles on GenomeWeb Last Week: Illumina, Liquid Biopsy, Thermo Fisher Scientific, and More Becton Dickinson Sues Beckman Coulter Over Cell Analysis, Sorting IP The Scan Another Resignation According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug. Novavax Finds Its Vaccine Effective Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19. Can't Be Used The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports. PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.